Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Feb 2004

Wagner Lars M, Crews Kristine R, Iacono Lisa C, Houghton Peter J, Fuller Christine E, McCarville M Beth, Goldsby Robert E, Albritton Karen, Stewart Clinton F, Santana Victor M

Abstract excerpt

PURPOSE: The purpose is to estimate the maximum-tolerated dose (MTD) of temozolomide and irinotecan given on a protracted schedule in 28-day courses to pediatric patients with refractory solid tumors. EXPERIMENTAL DESIGN: Twelve heavily pretreated patients received 56 courses of oral temozolomide at 100 mg/m(2)/day for 5 days combined with i.v. irinotecan given daily for 5 days for 2 consecutive weeks at either...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Area Under Curve
Share to Base Pair Mismatch

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Camptothecin

Share to Dacarbazine

Share to Irinotecan

Share to Maximum Tolerated Dose

Share to O(6)-Methylguanine-DNA Methyltransferase

Share to Temozolomide

Source

Identifiers

PMID: 14871959
DOI: 10.1158/1078-0432.ccr-03-0175

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors.PMID 14871959Read ↗

Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: a new approach to neuroblastoma therapy consortium study.Semantic proximity Read ↗

Phase 1 study of oxaliplatin and irinotecan in pediatric patients with refractory solid tumors: a children's oncology group study.Semantic proximity Read ↗

Reducing irinotecan-associated diarrhea in children.Semantic proximity Read ↗

A phase I pharmacologic and pharmacogenetic trial of sequential 24-hour infusion of irinotecan followed by leucovorin and a 48-hour infusion of fluorouracil in adult patients with solid tumors.Semantic proximity Read ↗

Phase I pharmacokinetic, food effect, and pharmacogenetic study of oral irinotecan given as semisolid matrix capsules in patients with solid tumors.Semantic proximity Read ↗

A phase 1 trial of intravenous liposomal irinotecan in patients with recurrent high-grade glioma.Semantic proximity Read ↗

Biochemical correlates of temozolomide sensitivity in pediatric solid tumor xenograft models.Semantic proximity Read ↗

Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma, or leukemiaSemantic proximity Read ↗

Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients.Semantic proximity Read ↗

UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but not severe toxicity in patients receiving low-dose irinotecan.Semantic proximity Read ↗

In vivo Evaluation of Ixabepilone (BMS247550), A Novel Epothilone B Derivative, against Pediatric Cancer ModelsSemantic proximity Read ↗

Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.